Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 02, 2024 08:00 ET | Source: 23andMe, Inc.

23andMe Special Committee responds to CEO’s take-private proposal

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical...
August 01, 2024 08:00 ET | Source: 23andMe, Inc.

23andMe Announces CEO’s Take-Private Proposal

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, has received a preliminary non-binding...
July 25, 2024 16:45 ET | Source: 23andMe, Inc.

23andMe to Report Q1 FY2025 Financial Results

SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people...
July 25, 2024 07:30 ET | Source: 23andMe, Inc.

Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research

SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading genetic health and biopharmaceutical company, in collaboration with 20 lung cancer advocacy...
June 28, 2024 07:00 ET | Source: 23andMe, Inc.

23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel

SOUTH SAN FRANCISCO, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading preventive health and therapeutics company, and Nightingale Health Plc, a pioneer in...
June 05, 2024 07:00 ET | Source: 23andMe, Inc.

23andMe Launches New Genetic Report on Bipolar Disorder

SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today released a new genetic Bipolar Disorder...
June 04, 2024 07:00 ET | Source: 23andMe, Inc.

23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community

SUNNYVALE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, and the Colorectal Cancer Alliance...
June 03, 2024 08:00 ET | Source: 23andMe, Inc.

23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting

– 23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit, including one confirmed partial response – 23ME-00610 monotherapy continues to demonstrate acceptable safety and...
May 29, 2024 08:00 ET | Source: 23andMe, Inc.

Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history

The LRRK2 variant is strongly associated with symptoms of Parkinson’s disease (PD) that are different from non-variant carriers with the diseaseThe study revealed novel findings of genetic “hotspots”...
May 23, 2024 16:05 ET | Source: 23andMe, Inc.

23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the fourth...